<DOC>
	<DOCNO>NCT02566655</DOCNO>
	<brief_summary>The purpose study evaluate safety intravenous infusion fucosylated autologous bone marrow cell new therapy patient establish osteoporosis prospective , single-center , open , non-randomized unblinded clinical trial .</brief_summary>
	<brief_title>Clinical Trial Intravenous Infusion Fucosylated Bone Marrow Mesenchyme Cells Patients With Osteoporosis</brief_title>
	<detailed_description />
	<mesh_term>Fractures , Bone</mesh_term>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Spinal Fractures</mesh_term>
	<criteria>Patients establish osteoporosis accord standard clinical criterion . Patients give write informed consent participate study consent . Meet inclusion criterion Patients concomitant systemic disease opinion investigator . Patients rheumatoid arthritis , ankylose spondylitis , chronic polyarticular arthritis . Current patient neoplasm history malignancy last 10 year except basal carcinoma epidermoid skin . Patients genetic disorder associate secondary osteoporosis : Hemochromatosis , hypophosphatasia , osteogenesis imperfecta , EhlersDanlos syndrome , Marfan syndrome , Riley Day , porphyria , storage disease syndrome . Patients receive immunosuppressive chemotherapy could interfere process cell proliferation . Transplant patient : bone marrow , kidney , liver , heart , lung . Patients clinical criterion anesthetic contraindicate well sedation bone marrow extraction . Patients participate clinical trial last 6 month . Patients positive serology hepatitis B , hepatitis C HIV . Patients inability understand inform consent . Patients pregnant breastfeed actively . Patients physically fertile , defined woman physiologically capable become pregnant , UNLESS use reliable method contraception .</criteria>
	<gender>Female</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>